| Project/Area Number |
24659493
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Pediatrics
|
|---|
| Research Institution | Nagoya University |
|---|
Principal Investigator |
KIMURA Hiroshi 名古屋大学, 医学(系)研究科(研究院), 教授 (30303621)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
GOSHIMA Fumi 名古屋大学, 大学院医学系研究科, 助教 (70201499)
KAMAKURA Maki 名古屋大学, 大学院医学系研究科, COE特任助教 (80437003)
ITO Yoshinori 名古屋大学, 医学部附属病院, 講師 (20373491)
|
|---|
| Project Period (FY) |
2012-04-01 – 2014-03-31
|
| Project Status |
Completed (Fiscal Year 2013)
|
| Budget Amount *help |
¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2013: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2012: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | 細胞療法 / 慢性活動性EBV感染症 / 母子間マイクロキメリズム / 免疫寛容 / EBウイルス / 母子間ﾏｲｸﾛｷﾒﾘｽﾞﾑ |
|---|
| Research Abstract |
Severe Epstein-Barr virus (EBV) infections, such as chronic active EBV infection and EBV-associated hemophagocytic lymphohistiocytosis, are refractory to therapies and intractable diseases. Recently, fetal-maternal lymphohematopoietic microchimerism can be detected in blood from healthy individuals, and immunological tolerance exists between mothers and children. In this study, in order to develop novel therapies for severe EBV infections, fundamental studies including the proof of fetomaternal microchimerism have been performed for establishing cell therapy.
|
